Loading stock data…
ADMA
$8.12+0.06 (+0.74%)
After Hours$8.12+0.00 (+0.00%)· Last close Jun 9
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ADMA Biologics, Inc. in the Healthcare sector is trading at $8.12. Wall Street consensus targets $16.75 (4 analysts), implying a +106.3% move over the next 12 months. The stock is currently near its 52-week low of $7.21, remaining 44.5% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +106.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 35) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$8.12
Potential Downside
0%
Whystock Fair Value$8.12
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$16.75+106.3%
Range$12.00 – $20.00
Fundamentals
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
42.36%
Volume
Today's trading volume
3.01M
Recent News
Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
US High Growth Tech Stocks with Promising Potential
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by 26%, with earnings expected to grow by 16% per annum in the coming years. In this environment of steady growth and promising earnings projections, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on emerging technological trends.
New Strong Sell Stocks for June 3rd
AOS, ADMA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on June 3rd, 2026.
ADMA Biologics (ADMA) Valuation After 2026 Guidance Reset And BIVIGAM Headwinds
ADMA Biologics (ADMA) is back in focus after updating its 2026 revenue and adjusted EBITDA outlook and withdrawing its longer term guidance, as investors weigh strong ASCENIV growth against pressure in BIVIGAM. See our latest analysis for ADMA Biologics. The updated 2026 outlook and withdrawn longer term guidance have coincided with sharp share price pressure, with the stock down 55% year to date and the 1 year total shareholder return declining 61%, even though the 5 year total shareholder...
ADMA Biologics (ADMA) Receives FDA Label Expansion for ASCENIV
ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best cheap stocks under $10 to buy in June. On May 4, ADMA Biologics received FDA approval to expand the label for its specialty biologic, ASCENIV, to include pediatric patients aged two years and older. Previously, the treatment was restricted to primary humoral immunodeficiency/PI patients aged 12 […]